As conflicts erupt throughout the globe regarding so-called pay-for-delay schemes, in which a pharmaceutical company pays its generic counterpart to delay the sale of the often-cheaper drugs, reports say a new South African law is adding fuel to the discussion.
A new policy proposed in South Africa would reportedly allow the government to duplicate brand name drugs and sell them for lower costs, similar to the way generics are sold.
Such a procedures is already in place in India.
Reports say based on the effects in India, such government action can weaken patent protection on some drugs. In India, for example, Novartis and Bayer have seen weakened regulatory protection of the patent for one of their cancer treatments.
Pharmaceutical giants are now discussing how to resist the new policy, sparking a worldwide debate. According to US consultant to the Innovative Pharmaceutical Association of South Africa, “South Africa is now ground zero for the debate on the value of strong IP protection.” The results of pharmaceutical companies’ fights against the government rules are likely to be felt throughout the globe in major drug markets, like Brazil, say reports.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI